Neutral Sphingomyelinase Behaviour in Hippocampus Neuroinflammation of MPTP-Induced Mouse Model of Parkinson's Disease and in Embryonic Hippocampal Cells by Cataldi, S et al.
Research Article
Neutral Sphingomyelinase Behaviour in Hippocampus
Neuroinflammation of MPTP-Induced Mouse Model of
Parkinson’s Disease and in Embryonic Hippocampal Cells
Samuela Cataldi,1 Cataldo Arcuri,2 Stéphane Hunot,3 François-Pierre Légeron,3
Carmen Mecca,2 Mercedes Garcia-Gil,4 Andrea Lazzarini,5 Michela Codini,1
Tommaso Beccari,1 Anna Tasegian,1 Bernard Fioretti,6 Giovanna Traina,1
Francesco Saverio Ambesi-Impiombato,7 Francesco Curcio,7 and Elisabetta Albi1
1Department of Pharmaceutical Science, University of Perugia, Perugia, Italy
2Department of Experimental Medicine, University of Perugia, Polo Unico Sant’Andrea delle Fratte, Piazzale Gambuli,
06132 Perugia, Italy
3Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127,
Institut du Cerveau et de la Moelleépinière (ICM), 75013 Paris, France
4Department of Biology and Interdepartmental Research Center Nutrafood “Nutraceuticals and Food for Health”, University of Pisa,
Pisa, Italy
5CRABiON-Perugia, Via Ponchielli 4, 06073 Perugia, Italy
6Department of Chemistry, Biology and Biotechnology, Via Elce di sotto, 06123 Perugia, Italy
7Dipartimento di Area Medica (DAME), University of Udine, P.le M. Kolbe 4, 33100 Udine, Italy
Correspondence should be addressed to Elisabetta Albi; elisabetta.albi@unipg.it
Received 24 May 2017; Revised 16 September 2017; Accepted 26 September 2017; Published 16 November 2017
Academic Editor: Vinod K. Mishra
Copyright © 2017 Samuela Cataldi et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Neutral sphingomyelinase is known to be implicated in growth arrest, differentiation, proliferation, and apoptosis. Although
previous studies have reported the involvement of neutral sphingomyelinase in hippocampus physiopathology, its behavior
in the hippocampus during Parkinson’s disease remains undetected. In this study, we show an upregulation of inducible
nitric oxide synthase and a downregulation of neutral sphingomyelinase in the hippocampus of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine- (MPTP-) induced mouse model of Parkinson’s disease. Moreover, the stimulation of neutral
sphingomyelinase activity with vitamin 1,25-dihydroxyvitamin D3 reduces specifically saturated fatty acid sphingomyelin by
making sphingomyelin a less rigid molecule that might influence neurite plasticity. The possible biological relevance of the
increase of neutral sphingomyelinase in Parkinson’s disease is discussed.
1. Introduction
Neuroinflammation was described to be involved in the
pathogenesis of Parkinson’s disease [1]. It has been previously
demonstrated that in 1-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine- (MPTP-) induced mouse model of Parkinson’s
disease (PD), the midbrain is characterized by an overex-
pression of e-cadherin and interleukin-6 accompanied by
a reduction of tyrosine hydroxylase for dopamine synthesis
[2]. On the other hand, in MPTP-induced Parkinson,
the increase in proinflammatory cytokines was attenuated
by using FK506, an immunosuppressant drug [3]. Castro-
Hernández et al. demonstrated that MPTP-induced dopami-
nergic damage had time-dependent effects; the neurotoxic
effect was evident mainly in the ventral region of the hip-
pocampus [4]. Recently, an age-dependent hippocampal
volume loss with cognitive impairment was shown in patients
with PD [5]. Lipopolysaccharide-induced neuroinflammation
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changed the lipid composition of hippocampal plasma
membranes from rats [6], and modulation of neuroinflam-
mation by sphingolipids has been described [7]. Glucocor-
ticosterone induced the release of ceramide into the
extracellular space of the hippocampus, by reducing neuro-
nal stem cell proliferation [8]. Ceramides are a class of
sphingolipid, produced by sphingomyenase (SMase) and
de novo synthesis that regulate various cell functions such
as proliferation, differentiation, senescence, apoptosis,
autophagy, migration, and intracellular trafficking [9]. Neu-
tral SMase (nSMase)/ceramide pathway was described to be
involved in hippocampus inflammation during ischemia-
associated neuronal damage [10]. The inhibition of nSMase
activity reduced ceramide accumulation in astrocytes and
alleviated neuronal damage [10]. Moreover, the SMase
inhibited the ligand binding function of serotonin1A recep-
tors [11] and reduced M1 muscarinic receptors [12] in the
hippocampus. The hydrolysis of sphingomyelin (SM) with
production of sphingosine-1-phosphate increased hippo-
campal neuron excitability [13]. So far, there are no data
on nSMAse in the hippocampal neuroinflammation in
PD. Here, we have investigated the possible variation of
nSMase in relation to the inducible nitric oxide synthase
(iNOS) in the hippocampal dentate gyrus of mice with
MPTP-induced PD. Our results showed reduction of
nSMase. As in the adult dentate gyrus neurogenesis occurs
[14], we used 1,25-dihydroxyvitamin D3 (VD3) that
induces cell differentiation via nSMase [15, 16] to stimulate
nSMase in embryonic hippocampus cells. Then, we studied
the variations of SM species in order to understand the pos-
sible importance of the reduction of nSMase in PD.
2. Methods
2.1. Animals. Ten- to twelve-week-old male C57BL/6J mice
weighing 25–30 g (CERJ, France) were used as previously
reported [2]. Mice were kept in a temperature-controlled
room (23°C± 1°C) under a 12-hour light/dark cycle with
access to food and water ad libitum. Animal treatments were
performed according to ethical regulations and guidelines
(Guide for the Care and Use of Laboratory Animals, NIH
publication number 85-23, revised 1985) and the European
Communities Council Directive 86/609/EEC. Experimental
protocols were performed following the French national
chart for ethics of animal experiments (articles R 214-87 to
126 of the “Code rural”) and received approval from the eth-
ical committee number 5 “Charles Darwin” and from the
ICM animal care and use committee.
2.2. Reagents. Anti-nSMase and anti-NOS2 (M-19) were
from Santa Cruz Biotechnology Inc. (California, USA).
SDS-PAGE molecular weight standard was from Bio-Rad
Laboratories (Hercules, CA, USA). VD3 was obtained
from DBA Italia (Segrate, Milan, Italy). Dulbecco’s modi-
fied Eagle’s medium (DMEM), bovine serum albumin,
tetramethylrhodamineisothiocyanate-conjugated goat anti-
rabbit IgG, and MPTP-HCl were from Sigma Chemical
Co. (St. Louis, Missouri, USA). Lipid standards 16:0SM,
18:1SM, and 24:0SM were purchased from Avanti (Avanti
Polar, Alabaster, AL, USA).
2.3. MPTP Injection and Tissue Preparation. Animals were
treated as previously reported [2]. Groups of mice (n = 5)
received MPTP under an acute protocol. Mice were given
4 i.p. injections of MPTP-HCl 2 hours apart and at a dose
of 20mg/kg (free-base). They were euthanized 7 days after
the last MPTP injection. Control mice received an equivalent
volume of 0.9% NaCl solution. Removed brains were post-
fixed overnight in fresh 4% paraformaldehyde (PFA)/phos-
phate-buffered saline (PBS) solution, cryoprotected with
30% sucrose in 0.1M PB and frozen in isopentane (−30°C).
Brain free-floating sections (20 μm thick) encompassing the
hippocampus were prepared using a freezing microtome
(Microm, Germany). Sections were stored at −70°C until use.
2.4. Immunofluorescence. The cryostat sections were incu-
bated overnight with 3% (w/v) bovine serum albumin
(BSA) and 1% (w/v) glycine in PBS to block nonspecific sites
as previously reported [17]. Then, sections were incubated
with anti-iNOS or anti-nSMase primary antibodies diluted
1 : 100 in 3% (w/v) BSA in PBS for 1 hr, washed three times
in 0.1% (v/v) Tween-20 in PBS and two times in PBS, incu-
bated with tetramethylrhodamineisothiocyanate-conjugated
anti-rabbit IgG for 1 h, diluted 1 : 50 in 3% (w/v) BSA in
PBS, and washed as above. The samples were mounted in
80% (w/v) glycerol, containing 0.02% (w/v) NaN3 and p-
phenylenediamine (1mg/ml) in PBS to prevent fluorescence
fading. The antibody incubations were done in a humid
chamber at room temperature. Fluorescent analysis was per-
formed on a DMRB Leica epi-fluorescent microscope
equipped with a digital camera.
2.5. Cell Culture and Treatments. Immortalized hippocampal
neurons HN9.10e (kind gift of Dr. Kieran Breen, Ninewells
Hospital, Dundee, UK) were cultured as previously reported
[16]. VD3, dissolved in absolute ethanol as a vehicle at the
100 nM physiological concentration, was added to the cul-
tures for 48 h; in control samples, only absolute ethanol was
added [16]. The cells were used in part for the analysis of total
protein content, in part for enzyme activity assay, and in part
for lipidomic analysis of SM.
2.6. Protein Content. Total protein concentration was evalu-
ated spectrophotometrically at 750nm by using albumin
bovine serum as a standard, as previously reported [18].
2.7. Enzyme Activity Assay. Enzymes involved in ner-
vous cell differentiation (nSMase) [16] and lysosomal
enzymes involved in nervous cell damage such as acid
sphingomyelinase (aSMase), β-hexosaminidase, α-fucosi-
dase, β-mannosidase, α-mannosidase, β-galactosidase, and
β-glucocerebrosidase [19, 20] were assayed. The nSMase
activity was measured as previously reported [21]. Briefly,
14C–SM (final specific activity 1.08 Ci/mol) was used as sub-
strate. The reaction mixture contained 0.1M Tris/HCl
pH7.6, 0.1mM 14C–SM, 6mM MgCl2, 0.1% Triton X-100,
and 100 μg protein to a final volume of 0.1ml. Incubations
were performed at 37°C for 45min. 2ml chloroform and
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methanol (2 : 1) were used to stop the reaction, and 0.4ml
of 0.5% NaCl was added. Samples were centrifuged at
2000 rpm 10min, and 0.5ml of the upper phase was diluted
in counting vials with 10ml Ecoscint A and 1ml distilled
water; radioactivity was measured with a Packard liquid scin-
tillation analyzer. The aSMase activity was measured as previ-
ously reported [22]. Briefly, the substrate was prepared as
nSMase. The reaction mixture contained 1mM EDTA,
pH5.0, 0.1mM 14C–SM, 250mM sodium acetate, 0.1% Triton
X-100, and 100 μg protein of NFL or nuclei to a final vol-
ume of 0.1ml. Conditions of incubation and radioactive
analysis were performed as nSMase. The β-hexosaminidase,
α-fucosidase, β-mannosidase, α-mannosidase, β-galactosi-
dase, and β-glucocerebrosidase enzymatic activities were
determined with the corresponding fluorogenic substrate
and reaction buffer, as previously reported [20]. The fluores-
cence was measured on a BMG Labtech FLUOstar OPTIMA
fluorometer (excitation wavelength = 360nm; emission wave-
length = 446nm).
2.8. Ultrafast Liquid Chromatography Tandem Mass
Spectrometry (UFLC-MS/MS). Lipids were extracted, and
16:0SM, 18:1SM, and 24:0SM standards were prepared as
previously reported [23]. Analysis was carried out by using
ultrafast liquid chromatography system tandem mass spec-
trometer Applied Biosystem (Shimadzu Italy s.r.l., Italy),
and 16:0SM, 18:1SM, and 24:0SM species were analyzed by
using external calibrators and identified as previously
reported [23]. All SM species were analyzed by identifying
the peaks on the basis of their molecular weight by using
standards as references [24].
2.9. Statistical Analysis. Three experiments were performed
for each analysis. Data are expressed as mean± S.D., and
t-test was used for statistical analysis between control
and experimental samples.
3. Results and Discussion
3.1. Results. iNOS inflammatory cytokine has been reported
to be highly expressed in striatum and substantia nigra of
animals with PD [25]. As the hippocampus is damaged
during PD [4, 5], we analyzed the difference of iNOS
expression in sections of hippocampus from normal and
MPTP-induced Parkinson mice. We showed dentate gyrus
by using DAPI signal (blue) in the nuclei, and we focused
the attention on the corner region (Figure 1). Immunofluo-
rescence staining with the anti-iNOS antibody (red) and
merged with DAPI (blue) revealed the higher expression of
iNOS in experimental than in control animals (Figure 1).
Since the iNOS function in inflammation is well established,
our results confirmed the neuroinflammation in the dentate
gyrus of the hippocampus from PD mice. In order to deter-
mine the relative contribution of nSMase during neuroin-
flammation in PD, the expression of nSMase protein was
measured in the same samples. The merged image with DAPI
signals (blue) in the nuclei and nSMase (red) showed a strong
reduction of nSMase in experimental sample. Consistent
with a significant role for SM in the brain [26], as SMase is
the enzyme that catalyzes SM hydrolysis, these data indi-
cated that nSMase could have a role in the dentate gyrus
function. At this moment, we do not have data about
the activity of nSMase in the hippocampus of the control
and PD-induced mice. Future studies will clarify this
point. Therefore, we then wondered what was the effect
of nSMase stimulation on the SM of hippocampal cells.
For this purpose, we conducted an in vitro study by using
VD3 that both stimulates nSMase activity and induces differ-
entiation of HN9.10e embryonic hippocampus cells [15, 16].
It would be very useful in the future to mimic the in vivo sit-
uation of PD mice by using HN9.10e cells after having
silenced nSMase expression. Physiological doses of VD3
[16] significantly increased nSMase activity following treat-
ment for 48h (Figure 2(a)). Then, we wanted to determine
if the elevations in enzymatic activity were specific for
nSMase or if it was a general response of the enzymes impor-
tant for the brain function regulation. Thus, enzyme activities
of aSMase, β-hexosaminidase, α-fucosidase, β-mannosidase,
α-mannosidase, β-galactosidase, and β-glucocerebrosidase
were quantified in untreated and VD3-treated HN9.10e
cells. The activity of all these enzymes remained unchanged
(Figures 2(a) and 2(b)). The experimental results revealed
that nSMase was specifically stimulated by VD3. Thus, we
hypothesized that its increase in activity could change the
SM profile. To test this hypothesis, we performed the anal-
ysis of SM species by UFLC-MS/MS. The results showed
that VD3 decreased 1.2-fold the amount of 16:0SM, and
1.70-fold that of 24:0SM (Figure 3(a)). To have a deeper
insight in SM species containing saturated or unsaturated
FAs, we evaluated the areas of all the peaks identified on
the basis of their molecular weight and analyzed their
values in relation to protein content. Significant decrease
in the levels of saturated molecular species was found for
16:0SM, 18:0SM, 20:0SM, 22:0SM, 24:0SM, and 26:0SM,
and significant increase was found for unsaturated molecu-
lar species 16:3SM, 16:4SM, 18:1SM, 20:4SM, 24:3SM,
26:2SM, and 26:3SM (Figure 3(b)). Then we compared
the changes in the total levels of SM species containing sat-
urated and unsaturated FAs. As reported in Figure 3(c), the
SM saturated FAs decreased and SM unsaturated FA
increased in VD3-treated cells compared with control cells.
3.2. Discussion. SMase is an indispensable enzyme for the
brain and plays an important role in signal transduction
pathways by regulating the level of SM and ceramide spe-
cies involved in physiological functions and pathological
diseases. A wide variety of studies has noted the diversity
of nSMase and aSMase functions during brain develop-
ment/stem cell differentiation and ischemic/degenerative/
stress responses [26, 27]. Recent evidence has highlighted
the role of nSMase in the physiopathology of the hippo-
campus [10–12]. The involvement of the hippocampus in
PD has been recently described [4, 5]. Yao et al. suggested
that hippocampal pathology makes a key contribution to
visual hallucinations in PD [28]. How hippocampus is
damaged in PD remains unclear. As we know that iNOS
is induced by inflammatory cytokines [25], we hypothe-
sized a neuroinflammation in the hippocampus of PD
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mice. At this point, the possible role of the nSMase down-
regulation in neuroinflammation remains obscure. Until
now, little is known about the specific nSMase role on
hippocampus health and/or disease. Gu et al. demon-
strated a considerable production of ceramide in astrocytes
during early cerebral ischemia accompanied by the induc-
tion of nSMase but not aSMase in the rat hippocampi,
with ceramide accumulation [29]. Also, Babenko and Sha-
khova reported that the nSMase, but not the aSMase,
increased in both the hippocampus and brain cortex dur-
ing aging, suggesting that redox-sensitive nSMase played
an important role in SM turnover dysregulation in both
the hippocampus and neocortex at old age [30]. The
authors thus indicated the increase of nSMase as an
adverse event. However, Norman et al. highlighted that
nSMase increased action potential frequency in hippocam-
pal neurons with a rapid increase in the levels of cera-
mides and S1P indicating the positive regulation of the
excitability of hippocampal neurons via nSMase [13].
Thus, at this point, the work on the topic is scarce and
the positive or negative role of the nSMase in the different
experimental conditions is discordant. Interestingly, we
used VD3 to stimulate nSMase activity in HN9.10e embry-
onic hippocampus cultured cells in order to study the spe-
cific role of this enzyme in the hippocampus. The lack of
involvement of aSMase, β-hexosaminidase, α-fucosidase,
iNOS
CTR
nSMase
CTR
Treated Treated
Figure 1: Hippocampus of untreated (control) or MPTP-treated (experimental) mice. The samples were treated as reported in Material and
Methods. (c) DAPI fluorescence image of the dentate gyrus of the hippocampus (10x magnification); in the square, detail enlarged in the
images of CTR (control) and Treated (experimental). (a, d) iNOS and (b, e) nSMase (100x magnification oil immersion)
immunofluorescence. The images represent the merged signals with DAPI signals (blue) in the nuclei and immunolabelling with anti-
iNOS or anti-nSMase (red).
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β-mannosidase, α-mannosidase, β-galactosidase, and β-
glucocerebrosidase in the VD3 response was consistent
with observations suggesting the specificity of nSMase role
in the hippocampus [13, 29, 30]. Thus, previous studies
were in line with our findings and therefore we have
considered a suitable experimental model to use VD3 to
potentiate the specific activity of nSMase and consequently
to study the specific effects on SM species of HN9.10e.
Notably, our results indicate that the increase of
nSMase activity reduces specifically saturated fatty acids
and consequently reduces the ratio saturated/unsaturated
fatty acids of SM. So we think that the mechanism under-
lying the increase in unsaturated fatty acids is not depen-
dent on a transformation of unsaturated to saturated fatty
acids but on a specific action of nSMase on saturated SM.
Since unsaturated fatty acids make the membrane more
fluid [31], we hypothesized that the changes of SM species
might determine enhanced dynamic properties of the cells
that are induced to differentiation by VD3 [32]. Manduca
et al. demonstrated that the inhibition of endocannabinoid
2-arachidonylglycerol (omega 6 fatty acid) degradation is
important for synaptic plasticity in n-3 polyunsaturated
fatty acid-deficient mice [33]. On the other hand, a diet
rich in polyunsaturated fatty acids in mice from the first
day of gestation improves plasticity in the brain of mice
at postnatal day [34]. Thus, another novel finding of our
study is that the reduction of saturated/unsaturated fatty
acid ratio induced by nSMase, by making SM a less rigid
molecule, might influence neurite plasticity. These data
would predict that nSMase stimulation could be useful
for the health of hippocampus in PD.
4. Conclusions
In conclusion, for the first time, we demonstrate that in the
hippocampus from PD-induced mice, the nSMase is strongly
reduced in association with neuroinflammation and that the
increase in nSMase activity following VD3 treatment in
HN9.10e cells decreases specifically only saturated SM.
Collectively, these results place nSMase as an essential
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Figure 2: HN9.10 embryonic hippocampal cells cultured in the presence or the absence of VD3 for 48 h. (a) nSMase and aSMase activity;
(b) β-hexosaminidase (β-hex), α-fucosidase (α-fuc), β-mannosidase (β-mann), α-mannosidase (α-mann), β-galactosidase (β-galact),
and β-glucocerebrosidase (β-gluc) activities. Data are expressed as the mean± S.D. of 3 independent experiments performed in
duplicate. ∗P < 0 001 versus the control sample.
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Figure 3: Sphingomyelin in control and vitamin D3-treated HN9.10 cells after 48 h of culture. (a) SM species studied by using 16:0SM,
18:1SM, and 24:0SM external calibrators. Data are expressed as nmol/mg protein and represent the mean± S.D. of three separated
experiments. (b) SM species studied by evaluating the areas of all the peaks identified on the basis of their molecular weight. Data are
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enzyme for hippocampus function. Further investigation of
the potential roles of nSMase in PD could provide a better
understanding of the biological relevance of its level and
activation in the hippocampus as well as the potential ben-
efits of targeting nSMase with VD3.
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